Biomea Fusion has dosed the first subject in the multiple myeloma (MM) cohort of Phase I COVALENT-101 clinical trial of BMF-219 in patients with relapsed/refractory (R/R) MM, acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), diffuse large B-cell lymphoma (DLBCL).
BMF-219 is an oral covalent menin inhibitor. It is the first menin inhibitor to be administered to subjects with R/R MM.
Go deeper with GlobalData
The multicentre, open-label, dose-escalation and dose-expansion trial will analyse the safety, tolerability and pharmacokinetics / pharmacodynamics of a once-a-day oral dose of BMF-219 in patients with R/R acute leukaemias, including AML and ALL.
Trial subjects include subpopulations for whom hindering of menin is anticipated to offer a treatment benefit, e.g., patients with MLL1/KMT2A gene rearrangements or NPM1 mutations.
The trial was extended to include cohorts for subjects with R/R MM and R/R DLBCL.
Subject enrolment is underway in AML and ALL cohorts while DLBCL and MM cohorts were initiated.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurthermore, activation of the site in North America is underway.
Compelling preclinical activity of BMF-219 in MM subtypes was reported specifically ones driven by MYC, a protein vital for the growth of various kinds of tumours.
Detecting the optimal biologic dose and recommended Phase II dose of BMF-219 monotherapy is the trial’s primary outcome measure.
Assessing the safety of BMF-219 through treatment-emergent adverse events and serious adverse events (SAEs) are the secondary outcome measures of the trial.
Biomea CEO, board chairman and co-founder Thomas Butler said: “Today, we have taken the first step to explore the clinical potential of BMF-219, a single-agent covalent menin inhibitor, in treating relapsed / refractory multiple myeloma patients.
“This represents the second cancer type, as well as the first cancer type outside of AML, to be studied with BMF-219.”
MM is a malignancy of plasma cells found in the bone marrow.
